Buchholz A, et al. - Researchers analyzed adherence to current labeling instructions concerning initial apixaban (a non–vitamin K oral anticoagulant approved for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF)] dosing in clinical practice. They also investigated factors related to inappropriate dose reduction. They found apixaban dosing was frequently inconsistent with labeling in clinical practice. Age, patient weight, and serum creatinine level were the factors found to be related to inappropriate dose reduction. For dose adjustment, the same factors were used as criteria. However, the criteria for dose reduction was not met by the 3 factors in underdosed patients.